New lab-made peptides kill breast cancer cells and still reach the brain
Original title: Combining brain-penetrating and anticancer peptides into bivalent-branched peptides conserves brain targeting and improves activity in vitro.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only tested on cells in the lab, not in people.
The short version
This is early lab work on a new way to get cancer drugs past the brain's protective wall.
What was studied. Researchers built two new branched peptides in the lab. Each one joins a peptide that crosses the brain's protective wall with a peptide that kills cancer cells.
What they found. About 40% of the new peptides crossed a lab model of the brain wall, much like the team's earlier peptide did. The new branched peptides killed triple-negative breast cancer cells more strongly than that earlier peptide. They also got inside cancer cells faster, but they were slightly more toxic.
What this means, and what it doesn't
What it could mean: This points to a peptide design that may one day carry cancer drugs into the brain. For now it mainly tells scientists which version is worth more testing.
What it doesn't mean: This does not mean a new treatment is coming soon. The work was done on cells in a dish, not in people or even in animals. No one has shown it is safe for a person or that it helps anyone live longer. It is not a cure, and it is far from everyday care.
Source: PubMed, November 4, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.